Ampio Pharmaceuticals Inc. (AMEX: AMPE) is 17.50% higher on its value in year-to-date trading and has touched a low of $0.26 and a high of $0.91 in the current 52-week trading range. The AMPE stock was last observed hovering at around $0.69 in the recent trading session, with the current loss setting it -0.03% off its average median price target of $4.00 for the next 12 months. It is also 83.5% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 83.5% higher than the price target low of $4.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $0.66, the stock is 15.22% and 16.57% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.55 million and changing -3.62% at the moment leaves the stock 24.74% off its SMA200. AMPE registered 59.30% gain for a year compared to 6-month loss of 14.17%. The firm has a 50-day simple moving average (SMA 50) of $0.5618 and a 200-day simple moving average (SMA200) of $0.5770.
The stock witnessed a 38.27% gain in the last 1 month and extending the period to 3 months gives it a 40.31%, and is 9.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.32% over the week and 12.39% over the month.
Distance from 52-week low is 153.92% and -27.46% from its 52-week high.
Ampio Pharmaceuticals Inc. (AMPE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ampio Pharmaceuticals Inc. (AMPE) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ampio Pharmaceuticals Inc. is expected to release its quarterly report on 09/02/2020 and quarterly earnings per share for the current quarter are estimated at -$0.04.The EPS is expected to shrink by -122.50% this year.
Ampio Pharmaceuticals Inc. (AMPE) Top Institutional Holders
80 institutions hold shares in Ampio Pharmaceuticals Inc. (AMPE), with 14.26M shares held by insiders accounting for 8.65% while institutional investors hold 13.21% of the company’s shares. The shares outstanding are 159.05M, and float is at 150.60M with Short Float at 8.09%. Institutions hold 12.07% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 5.35 million shares valued at $2.22 million. The investor’s holdings represent 3.25% of the AMPE Shares outstanding. As of Mar 30, 2020, the second largest holder is SRS Capital Advisors, Inc. with 1.77 million shares valued at $0.73 million to account for 1.07% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.33 million shares representing 0.80% and valued at over $0.55 million, while CVA Family Office, LLC holds 0.71% of the shares totaling 1.17 million with a market value of $0.49 million.
Ampio Pharmaceuticals Inc. (AMPE) Insider Activity
A total of 0 insider transactions have happened at Ampio Pharmaceuticals Inc. (AMPE) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Ampio Pharmaceuticals Inc. (AMPE): Who are the competitors?
The company’s main competitors (and peers) include Aerie Pharmaceuticals Inc. (AERI) that is trading -46.26% down over the past 12 months. Flexion Therapeutics Inc. (FLXN) is 17.72% up on the 1-year trading charts. Short interest in the company’s stock has fallen -0.57% from the last report on May 14, 2020 to stand at a total of 12.26 million short shares sold with a short interest ratio of 8.02.